Daiwa Securities Group Inc. - 4D MOLECULAR THERAPEUTICS IN ownership

4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.

Quarter-by-quarter ownership
Daiwa Securities Group Inc. ownership history of 4D MOLECULAR THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$61
-29.1%
4,7620.0%0.00%
-100.0%
Q2 2023$86
+4200.0%
4,762
+3563.1%
0.00%
Q1 2023$2
-33.3%
1300.0%0.00%
Q4 2022$3
-99.7%
130
+38.3%
0.00%
Q3 2022$1,0000.0%940.0%0.00%
Q2 2022$1,0000.0%940.0%0.00%
Q1 2022$1,000
-50.0%
940.0%0.00%
Q4 2021$2,000940.00%
Other shareholders
4D MOLECULAR THERAPEUTICS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Aquilo Capital Management, LLC 945,382$22,765,0005.92%
Octagon Capital Advisors LP 831,267$20,017,0004.15%
BVF INC/IL 2,005,862$48,301,0001.81%
Casdin Capital, LLC 1,115,555$26,863,0000.68%
Eagle Health Investments LP 57,090$1,375,0000.47%
Soleus Capital Management, L.P. 100,800$2,427,0000.37%
VIKING GLOBAL INVESTORS LP 3,937,914$94,825,0000.29%
ArrowMark Colorado Holdings LLC 1,029,897$24,800,0000.19%
Perceptive Advisors 750,512$18,072,0000.12%
Virtus ETF Advisers LLC 7,642$184,0000.08%
View complete list of 4D MOLECULAR THERAPEUTICS IN shareholders